
CPP
News & Events
-
July 18, 2023
C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships
C-Path ts activity in Europe and broaden its global operations. C-Path operates in Europe as a nonprofit organisation that builds consensus among its stakeholders from around the world to improve public health. The organisation shares expertise, data, risks and costs to move regulatory science forward.
-
July 6, 2023
Multistakeholder Collaborations Are Vital to Advancing Technologies in Parkinson’s
C-Path and the Center for Health + Technology (CHeT) at University of Rochester today announced the release of two seminal publications about digital health technologies for Parkinson’s. These technologies, such as smartphones and wearable sensors, offer an opportunity for objective, frequent and remote assessment of people with Parkinson’s.
-
June 20, 2023
C-Path’s Integrated Clinical Trial Database to Help Advance Research in Parkinson’s
TUCSON, Ariz., June 20, 2023 — Critical Path Institute (C-Path), an independent nonprofit organization, today announced it is providing access to the Critical Path for Parkinson’s (CPP) Integrated Parkinson’s Database to external qualified researchers. With 10 million people living with Parkinson’s worldwide, the fastest growing degenerative neurological condition, collaboration and data sharing are crucial to...... -
April 25, 2023
C-Path Europe: A Global Vision of Success
TUCSON, Ariz. and AMSTERDAM, April 26, 2023 — As an organization that generates regulatory-endorsed solutions and methodologies to accelerate drug development, Critical Path Institute (C-Path) today shared a year-in-review of its European-focused activities to advance global regulatory science. “We are pleased with the progress and continued development of our global efforts in the regulatory and...... -
December 20, 2022
C-Path Receives Letter of Support from EMA for Parkinson’s Disease Clinical Trial Simulation Platform
C-Path today announced that the European Medicines Agency (EMA) has issued a letter of support for the Critical Path for Parkinson’s (CPP) Consortium’s Model-based Clinical Trial Simulation Platform to Optimize Design of Efficacy Evaluation Studies in Parkinson’s Disease (PD).